Acasă
Traduceri
Literatura locală
Semnalări
Contact
EN
|
Un articol din septembrie 2006, din Wall Street Journal anunța
că firma Boston Scientific, mare producător de stent-uri,
ar fi declarat că stent-urile acoperite cu substanțe farmacologic
active (drug-eluting) ar fi afectate de rate sporite de trombozare
tardivă [1].
Literatura asupra acestui subiect pare să cuprindă
[2,3,4,5,6,]
-
Boston Scientific admits stent risks
- J Am Coll Cardiol. 2006 Jul 4;48(1):193-202. Epub 2006 May 5.
Pathology of drug-eluting stents in humans: delayed healing and late
thrombotic risk. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R,
- Circulation. 2003 Oct 7;108(14):1701-6. Epub 2003 Sep 22.
Pathological mechanisms of fatal late coronary stent thrombosis in humans. Farb A, Burke AP, Kolodgie FD, Virmani R,
- J Am Coll Cardiol. 2005 Mar 15;45(6):947-53.
Thirty-day incidence and six-month clinical outcome of thrombotic stent
occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW,
- J Am Coll Cardiol. 2005 Mar 15;45(6):954-9.
Drug-eluting stent thrombosis: results from a pooled analysis including 10
randomized studies. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C,
- Am J Cardiol. 2006 Aug 1;98(3):352-6. Epub 2006 Jun 12.
Frequency of and risk factors for stent thrombosis after drug-eluting
stent implantation during long-term follow-up. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ,
|
|